Ihnatko Ya. Ya., Derbak M. A., Chubirko K. I., Moskal O. M.

FEATURES OF THE FUNCTIONAL STATE OF THE LIVER AND INDICATORS OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH CORONARY HEART DISEASE COMBINED WITH NON-ALCOHOLIC FATTY LIVER DISEASE

---

Show/Download

About the author:

Ihnatko Ya. Ya., Derbak M. A., Chubirko K. I., Moskal O. M.

Heading:

CLINICAL AND EXPERIMENTAL MEDICINE

Type of article:

Scientific article

Annotation:

Long-term CHD comorbid with NAFLD leads to acceleration of atherogenesis, imbalance of ED and adipocytokines. To compare indicators of the liver functional state, levels of adipocytokines, C-reactive protein and marker of endothelial dysfunction in patients with CHD comorbid with and without NAFLD was the aim of research. 145 patients with CHD comorbid with NAFLD and 100 patients with CHD were examined. When analyzing the obtained laboratory parameters characterizing the liver functional state, it was established that in patients with CHD comorbid with NAFLD, a significant moderate elevation in the levels of ALT and AST was registered, which characterizes the presence of cytolysis syndrome. An imbalance of adipocytokines was also found in these patients: a decline in the concentration of adiponectin, an elevation in the level of resistin, and a decline in the ratio of adiponectin to resistin. A substantive increase in the serum level of ADMA and CRP in patients with combined pathology indicates the presence of ED against the background of activation of systemic inflammation, which may have pathogenetic significance in the growing of CHD comorbid with NAFLD.

Tags:

Bibliography:

1. Zaiats IO. Prohnozuvannia ryzyku rozvytku sertsevo-sudynnykh uskladnen ta udoskonalennia likuvannia khvorykh pokhyloho viku z ishemichnoiu khvoroboiu sertsia ta suputnoiu zalizodefitsytnoiu anemiieiu [dysertatsiia]. Dnipro: Dniprovskyi derzhavnyi medychnyi universytet, Ministerstvo Okhorony Zdorovia Ukrainy; 2023. 183 s. [in Ukrainian].
2. Almeida AG. MINOCA and INOCA: Role in Heart Failure. Curr Heart Fail Rep. 2023;20(3):139-150.
3.  Jensen RV, Hjortbak MV, Bøtker HE. Ischemic heart disease: an update. Sem Nucl Med. 2020;50(3):195-207.
4. Kibel A, Lukinac AM, Dambic V, Juric I, Selthofer-Relatic K, others. Oxidative stress in ischemic heart disease. Oxid Med Cell Longev. 2020;2020:1-30.
5. Pourrajab B, Naderi N, Janani L, Hajahmadi M, Mofid V, Dehnad A, et al. The impact of probiotic yogurt versus ordinary yogurt on serum sTWEAK, sCD163, ADMA, LCAT and BUN in patients with chronic heart failure: a randomized, triple-blind, controlled trial. J Sci Food Agric. 2022;102(13):6024-35.
6. Dowsett L, Higgins E, Alanazi S, Alshuwayer NA, Leiper FC, Leiper J. ADMA: a key player in the relationship between vascular dysfunction and inflammation in atherosclerosis. J Clin Med. 2020;9(9):3026-29.
7. Sušić L, Maričić L, Šahinović I, Kralik K, Klobučar L, Ćosić M, et al. The Relationship of Left Ventricular Diastolic Dysfunction and Asymmetrical Dimethylarginine as a Biomarker of Endothelial Dysfunction with Cardiovascular Risk Assessed by Systematic Coronary Risk Evaluation2 Algorithm and Heart Failure—A Cross-Sectional Study. Int J Environ Res Public Health. 2023;20(5):33-44.
8. Arslan U, Yenerçaug M. Relationship between non-alcoholic fatty liver disease and coronary heart disease. World J Clin Cases. 2020;8(20):1-13.
9. Chew NWS, Kannan S, Chong B, Chin Y, Muthiah M. The heart of NAFLD. Front Med. 2023;10:1-3.
10. Targher G, Corey KE, Byrne CD. NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. Diabetes & Metab. 2021;47(2):12-15.
11. Toh JZK, Pan X-H, Tay PWL, Ng CH, Yong JN, Xiao J, et al. A meta-analysis on the global prevalence, risk factors and screening of coronary heart disease in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2022;20(11):2462-73.
12. Mantovani A, Dalbeni A. NAFLD, MAFLD and DAFLD. Dig Liver Dis. 2020;52(12):1519-20.
13. Khukhlina OS, Kuzminska OB, Antofiichuk TM, Kotsiubiichuk ZIa, Hryniuk OIe, Kropyva VV. Stan systemy fibrynolizu ta proteolizu, homeostazu monooksydu nitrohenu, plazmovoho ta trombotsytarnoho hemostazu u khvorykh na nealkoholnyi steatohepatyt pry komorbidnosti z ishemichnoiu khvoroboiu sertsia. Ukrainskyi zhurnal medytsyny, biolohii ta sportu. 2019;4(6):217-22. [in Ukrainian].
14. Rozhdestvenska AO. Diahnostychne ta prohnostychne znachennia kalistatynu u khvorykh na nealkoholnu zhyrovu khvorobu pechinky na tli hipertonichnoi khvoroby. Kharkiv: Kharkivskyi natsionalnyi medychnyi universytet, Ministerstvo Okhorony Zdorovia Ukrainy; 2022. 210 s. [in Ukrainian].
15. Pivtorak KV. Endotelialna dysfunktsiia ta nealkoholna zhyrova khvoroba pechinky. Vinnytsia: Nova Knyha; 2022. 192 s. [in Ukrainian].
16. Kushnir IE. Nealkoholna zhyrova khvoroba pechinky: suchasni metody diahnostyky ta stratehii likuvannia. Suchasna hastroenterolohiia. 2020;3:51-61. [in Ukrainian].
17. Khukhlina OS, Kuzminska OB, Voievidka OS, Kotsiubiichuk ZIa, Kropyva VV. Klinichni osoblyvosti perebihu nealkoholnoho steatohepatytu za komorbidnosti z ishemichnoiu khvoroboiu sertsia. Ukrainskyi zhurnal medytsyny, biolohii ta sportu. 2019;4(1):149-54. [in Ukrainian].
18. Hryniuk OI. Klinichni ta patohenetychni osoblyvosti komorbidnoho perebihu nealkoholnoho steatohepatytu, ozhyrinnia ta khronichnoho obstruktyvnoho zakhvoriuvannia lehen, shliakhy korektsii [dysertatsiia]. Chernivtsi: Bukovynskyi derzhavnyi medychnyi universytet, Ministerstvo Okhorony Zdorovia Ukrainy; 2022. 326 s. [in Ukrainian].
19. Zhao S, Kusminski CM, Scherer PE. Adiponectin, leptin and cardiovascular disorders. Circ Res. 2021;128(1):136-49.
20. Yuxiang L, Fujiu K. Human resistin and cardiovascular disease. Int Heart J. 2020;61(3):421-3.
21. Anokhina HA. Nealkoholna zhyrova khvoroba pechinky yak multysystemne metabolitne zakhvoriuvannia: osoblyvosti profilaktyky ta likuvannia. Praktykuiuchyi likar. 2018;7(3):35-40. [in Ukrainian].
22. MOZ Ukrainy. Nakaz MOZ Ukrainy № 826 vid 06.11.2014 r. Pro zatverdzhennia unifikovanoho klinichnoho protokolu pervynnoi, vtorynnoi (spetsializovanoi) medychnoi dopomohy «Nealkoholnyi steatohepatyt». Kyiv: MOZ Ukrainy; 2014. 37 s. [in Ukrainian].
23. Archer AJ, Belfield KJ, Orr JG, Gordon FH, Abeysekera KWM. EASL clinical practice guidelines: non-invasive liver tests for evaluation of liver disease severity and prognosis. Frontline Gastroenterol. 2022;13(5):436-9.
24. Fiaschi T. Mechanisms of adiponectin action. International Journal of Molecular Sciences. MDPI. 2019;20(12):2894-97.
25. Khoramipour K, Chamari K, Hekmatikar AA, Ziyaiyan A, Taherkhani S, Elguindy NM, et al. Adiponectin: Structure, physiological functions, role in diseases, and effects of nutrition. Nutrients. 2021;13(4):1-15.
26. Askin L, Abus S, Tanriverdi O. Resistin and Cardiovascular Disease: A Review of the Current Literature Regarding Clinical and Pathological Relationships. Curr Cardiol Rev. 2022;18(1):1-7.
27. Wang B, Li F, Guo J, Wang C, Xu D, Li C. Effects of liver function, insulin resistance and inflammatory factors on vascular endothelial dilation function and prognosis of coronary heart disease patients complicated with NAFLD. Exp Ther Med. 2019;17(2):1306-11.

Publication of the article:

«Bulletin of problems biology and medicine», 2024 Issue 1, 172, 156-161 pages, index UDC 616.12-005.4:616.13.018.74:616.132.2-004.6:616.36-003.826-008]-074-097

DOI:

10.29254/2077-4214-2024-1-172-156-161